211 related articles for article (PubMed ID: 25179249)
1. Metabolic imaging in non-small-cell lung cancer radiotherapy.
Geets X; Sterpin E; Wanet M; Di Perri D; Lee J
Cancer Radiother; 2014 Oct; 18(5-6):402-5. PubMed ID: 25179249
[TBL] [Abstract][Full Text] [Related]
2. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
3. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
[TBL] [Abstract][Full Text] [Related]
4. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
5. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric implications of the addition of 18 fluorodeoxyglucose-positron emission tomography in CT-based radiotherapy planning for non-small-cell lung cancer.
Vinod SK; Kumar S; Holloway LC; Shafiq J
J Med Imaging Radiat Oncol; 2010 Apr; 54(2):152-60. PubMed ID: 20518880
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071
[TBL] [Abstract][Full Text] [Related]
8. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Møller DS; Nielsen TB; Brink C; Hoffmann L; Lutz CM; Drøgemüller Lund M; Hansen O; Schytte T; Khalil AA; Knap MM; Nyhus CH; Ottosson W; Sibolt P; Borissova S; Josipovic M; Persson G; Appelt AL
Radiother Oncol; 2017 Aug; 124(2):311-317. PubMed ID: 28688525
[TBL] [Abstract][Full Text] [Related]
10. Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study.
De Ruysscher D; Houben A; Aerts HJ; Dehing C; Wanders R; Ollers M; Dingemans AM; Hochstenbag M; Boersma L; Borger J; Dekker A; Lambin P
Radiother Oncol; 2009 Jun; 91(3):415-20. PubMed ID: 19195730
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the use of optimally respiratory gated 18F-FDG-PET in target volume delineation and its influence on radiation doses to the organs at risk in non-small-cell lung cancer patients.
Wijsman R; Grootjans W; Troost EG; van der Heijden EH; Visser EP; de Geus-Oei LF; Bussink J
Nucl Med Commun; 2016 Jan; 37(1):66-73. PubMed ID: 26440570
[TBL] [Abstract][Full Text] [Related]
12. The role of PET in target localization for radiotherapy treatment planning.
Rembielak A; Price P
Onkologie; 2008 Feb; 31(1-2):57-62. PubMed ID: 18268401
[TBL] [Abstract][Full Text] [Related]
13. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J; De Ruysscher D; Sonke JJ; Damen E; Sikorska K; Reymen B; van Elmpt W; Westman G; Fredberg Persson G; Dieleman E; Bjorkestrand H; Faivre-Finn C; Belderbos J
Radiother Oncol; 2019 Feb; 131():166-173. PubMed ID: 30327236
[TBL] [Abstract][Full Text] [Related]
14. Critical review of PET-CT for radiotherapy planning in lung cancer.
Senan S; De Ruysscher D
Crit Rev Oncol Hematol; 2005 Dec; 56(3):345-51. PubMed ID: 15990331
[TBL] [Abstract][Full Text] [Related]
15. [Radiotherapy of lung cancer: Any room left for elective mediastinal irradiation in 2011?].
Van Houtte P; Roelandts M; Mornex F
Cancer Radiother; 2011 Oct; 15(6-7):509-13. PubMed ID: 21873096
[TBL] [Abstract][Full Text] [Related]
16. [¹⁸F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients.
Petit SF; van Elmpt WJ; Oberije CJ; Vegt E; Dingemans AM; Lambin P; Dekker AL; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):698-705. PubMed ID: 20884128
[TBL] [Abstract][Full Text] [Related]
17. Defining target volumes for non-small cell lung carcinoma.
Senan S; Chapet O; Lagerwaard FJ; Ten Haken RK
Semin Radiat Oncol; 2004 Oct; 14(4):308-14. PubMed ID: 15558505
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer.
Lin P; Koh ES; Lin M; Vinod SK; Ho-Shon I; Yap J; Som S
Radiother Oncol; 2011 Nov; 101(2):284-90. PubMed ID: 21777988
[TBL] [Abstract][Full Text] [Related]
19. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC).
Greco C; Rosenzweig K; Cascini GL; Tamburrini O
Lung Cancer; 2007 Aug; 57(2):125-34. PubMed ID: 17478008
[TBL] [Abstract][Full Text] [Related]
20. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study.
Petit SF; Aerts HJ; van Loon JG; Offermann C; Houben R; Winkens B; Ollers MC; Lambin P; De Ruysscher D; Dekker AL
Radiother Oncol; 2009 Jun; 91(3):393-8. PubMed ID: 19328570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
